<SEC-DOCUMENT>0001571049-15-000350.txt : 20150122
<SEC-HEADER>0001571049-15-000350.hdr.sgml : 20150122
<ACCEPTANCE-DATETIME>20150122163049
ACCESSION NUMBER:		0001571049-15-000350
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150120
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150122
DATE AS OF CHANGE:		20150122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PHIBRO ANIMAL HEALTH CORP
		CENTRAL INDEX KEY:			0001069899
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				131840497
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36410
		FILM NUMBER:		15542242

	BUSINESS ADDRESS:	
		STREET 1:		GLENPOINTE CENTRE EAST, 3RD FLOOR
		STREET 2:		300 FRANK W. BURR BLVD., SUITE 21
		CITY:			TEANECK
		STATE:			NJ
		ZIP:			07666
		BUSINESS PHONE:		201-329-7300

	MAIL ADDRESS:	
		STREET 1:		GLENPOINTE CENTRE EAST, 3RD FLOOR
		STREET 2:		300 FRANK W. BURR BLVD., SUITE 21
		CITY:			TEANECK
		STATE:			NJ
		ZIP:			07666

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPP BROTHERS CHEMICALS INC
		DATE OF NAME CHANGE:	19980908
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1500148_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>UNITED
STATES</B><BR>
<B>SECURITIES AND EXCHANGE COMMISSION</B><BR>
<B>WASHINGTON, DC 20549</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>PURSUANT
TO SECTION 13 OR 15(D) OF THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>SECURITIES
EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
January 22, 2015 (January 20, 2015)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Phibro Animal Health Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(EXACT NAME OF REGISTRANT AS SPECIFIED IN
CHARTER)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U STYLE="text-decoration: none">Delaware</U></B></FONT></TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: none; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>01-36410</B></FONT></TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: none; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>13-1840497</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(State or other jurisdiction of</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(IRS Employer Identification No.)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>incorporation)</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Glenpointe Centre East, 3rd Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>300 Frank W. Burr Boulevard, Suite 21</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Teaneck, New Jersey 07666-6712</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of Principal Executive Offices,
including Zip Code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(201) 329-7300</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Registrant&rsquo;s telephone number,
including area code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former name or former address, if changed
since last report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if this
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 1.01 ENTRY INTO A MATERIAL DEFINTIVE AGREEMENT. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 20, 2015
(the &ldquo;Effective Date&rdquo;), Phibro Animal Health Corporation (the &ldquo;Company&rdquo;) and MJ Biologics, Inc. (&ldquo;MJB&rdquo;)
entered into a Collaboration and Distribution Agreement (the &ldquo;Collaboration Agreement&rdquo;), pursuant to which MJB and
the Company will collaborate on the development of certain animal vaccines against viral diseases and MJB granted the Company an
exclusive license to manufacture and distribute, in the United States, Canada and Mexico (&ldquo;North America&rdquo;), any vaccine
product which has been developed or is being sold by MJB as of the Effective Date or any other product which is developed under
the Collaboration Agreement. Pursuant to the terms of the Collaboration Agreement, the Company shall reimburse MJB&rsquo;s cost
of goods, make certain minimum base payments of $200,000 per month during the term of the Collaboration Agreement, subject to certain
offset provisions, and pay 50% of all gross margins over $400,000 per month. In connection with the Collaboration Agreement, MJB
assigned to the Company MJB&rsquo;s rights and responsibilities under an existing manufacturing and distribution agreement. The
Company shall be responsible for filing any patent that claims any technology developed during the term of the Collaboration Agreement
and shall have the sole and exclusive right, but not the obligation, to bring and control any legal action to enforce any patents
against any third party. The Collaboration Agreement contains representations, warranties, covenants and indemnification obligations
of both parties customary for the transactions contemplated thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and MJB,
on the Effective Date, also entered into a Technology License Agreement (the &ldquo;License Agreement&rdquo;), pursuant to which
MJB granted the Company an exclusive license to develop, manufacture and commercialize, outside of North America, vaccine products
using MJB&rsquo;s patents and know-how. The Company shall make quarterly royalty payments to MJB in an amount equal to a specified
percentage of net sales outside of North America during such quarter, subject to certain deductions for certain third party payment
obligations. The Company shall be responsible for filing any patent that claims any technology developed during the term of the
License Agreement and shall have the sole and exclusive right, but not the obligation, to bring and control any legal action to
enforce any patents against any third party. The License Agreement contains representations, warranties, covenants and indemnification
obligations of both parties customary for the transactions contemplated thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Collaboration Agreement
and the License Agreement both became effective as of the Effective Date and, unless otherwise terminated due to a material breach
or bankruptcy, both shall continue in effect until the earlier of the Closing Date of the Purchase Agreement described below, or
the termination of the Purchase Agreement without the Closing occurring thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and
MJB, on the Effective Date, also entered into an Intellectual Property Purchase Agreement (the &ldquo;Purchase
Agreement&rdquo;) pursuant to which the Company will acquire the intellectual property and certain other assets
comprising MJB&rsquo;s business relating to the development, manufacture, commercialization and distribution of animal
vaccines (collectively, the &ldquo;Purchased Assets&rdquo;). Subject to certain closing conditions, the closing date of
the acquisition (the &ldquo;Closing&rdquo; or the &ldquo;Closing Date&rdquo;) is anticipated to occur on or before January
1, 2021 (the &ldquo;Scheduled Closing Date&rdquo;). The Purchase Agreement also provides certain acceleration
provisions whereby, upon the occurrence of certain events, the Closing shall occur prior to the Scheduled Closing Date,
including, but not limited to: (a) the breach of certain MJB covenants contained in the Purchase Agreement, (b) the material
breach of a provision of the Purchase Agreement, the Collaboration Agreement or the License Agreement that is within
the reasonable control of MJB or its shareholders to cure, or (c) the filing of a petition under bankruptcy law by or against
MJB or William Marks (&ldquo;Marks&rdquo;), MJB&rsquo;s President. The Purchase Agreement also contains
representations, warranties, covenants, conditions and indemnification obligations of the parties customary for transactions
similar to those contemplated by</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the Purchase Agreement, including a covenant
by MJB not to compete with the Company and the vaccine business related to the Purchased Assets from the Effective Date until the
fifth anniversary of the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of
the Purchase Agreement, the Company made an upfront payment to MJB of $5,000,000 (the &ldquo;Initial Payment&rdquo;) and has agreed
to pay MJB a &ldquo;Closing Payment&rdquo; at Closing in an amount to be calculated based on the worldwide net sales of MJB&rsquo;s
vaccines for the 12 full months immediately prior to the Closing Date. Subject to offset in certain limited circumstances, the
Closing Payment will not be less than $10,000,000. In addition, MJB will be entitled to receive earn-out payments, from the Closing
Date through December 31, 2030, based on (i) a single-digit percentage of the net sales of any &ldquo;Royalty Product&rdquo; (as
defined in the License Agreement) that is being sold commercially by the Company at the time of or after the Closing in North America,
and (ii) a single-digit percentage of the net sales of any Royalty Product that is being sold commercially by the Company at the
time of or after the Closing outside of North America. The Purchase Agreement contains customary termination provisions, including
termination (i) by the written mutual consent of the parties, (ii) by the Company upon MJB&rsquo;s material breach, without waiver
or cure, of the Purchase Agreement or if the Company terminates the Collaboration Agreement or the License Agreement based on MJB&rsquo;s
material and uncured default thereof, (iii) by MJB upon the Company&rsquo;s material breach, without waiver or cure, of the Purchase
Agreement or if MJB terminates the Collaboration Agreement or the License Agreement based on the Company&rsquo;s material and uncured
default thereof, (iv) by the Company on or after June 30, 2021 if any of the conditions required to be satisfied by MJB have not
been fulfilled or become impossible to fulfill, (v) by MJB on or after June 30, 2021 if any of the conditions required to be satisfied
by the Company have not been fulfilled or become impossible to fulfill, or (vi) by the Company in the event any claim or action
for infringement, misappropriation or other violation of intellectual property rights is brought or threatened against either party
relating to any of the Purchased Assets, where there is a reasonable probability of success and, if successful, the result would
materially affect the Company&rsquo;s right to own the Purchased Assets or operate MJB&rsquo;s business. In the event of termination
of the Purchase Agreement, the Collaboration Agreement and the License Agreement shall automatically terminate and be of no further
force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is also
making a loan (the &ldquo;Loan&rdquo;) in the principal amount of $5,000,000 to Marks, pursuant to a promissory note (the &ldquo;Promissory
Note&rdquo;) which shall mature on the Closing Date. The Promissory Note bears interest at a variable rate equal to LIBOR plus
300 basis points. Interest accrued under the Promissory Note shall be paid semi-annually on each June 1 and January 1 during the
term of the Loan and the entire unpaid principal amount of the Loan, together with all outstanding and unpaid interest under the
Promissory Note, will be due and payable by Marks at Closing or over a period ending on the tenth anniversary of the Effective
Date in the event of a termination of the Purchase Agreement by the Company or upon the occurrence of certain customary events
of default contained in the Promissory Note. In connection with the issuance of the Promissory Note, the Company and Marks entered
into a Pledge Agreement, dated as of the Effective Date (the &ldquo;Pledge Agreement&rdquo;), to secure Marks&rsquo;s obligations
under the Promissory Note (the &ldquo;Obligations&rdquo;) by the grant to the Company of a security interest in all of Marks&rsquo;s
interests in MJB and all non-cash distributions or proceeds related to such interests (the &ldquo;Collateral&rdquo;). Until the
Obligations have been satisfied and discharged in full, Marks has agreed to certain covenants, including defending the Collateral
against any adverse third party claims and holding the Company harmless from such adverse claims, and Marks has also agreed not
to sell or otherwise transfer or encumber the Collateral, with certain limited exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Purchase Agreement, the Company and MJB also entered into a Security Agreement (the &ldquo;Security Agreement&rdquo;), dated
as of the Effective Date, under which MJB granted the Company a first priority security interest in the Purchased Assets to secure
MJB&rsquo;s obligations to the Company arising out of the Purchase Agreement or any of the other &ldquo;Transaction Documents&rdquo;
(as defined in the Purchase Agreement) (collectively, the &ldquo;Secured Obligations&rdquo;). The Security Agreement contains representations,
warranties and covenants of MJB customary for the transactions contemplated thereby and, upon the occurrence of certain customary
events of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">default, the Secured Obligations shall
immediately become due and payable, with the Company able to take possession of the Purchased Assets in connection with a Closing
under the Purchase Agreement prior to the Scheduled Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Marks, MJB and the
Company entered into a letter agreement on the Effective Date (the &ldquo;Marks Letter Agreement&rdquo;) pursuant to which Marks
has agreed to (i) a non-compete agreement substantially similar to MJB&rsquo;s non-competition covenant in the Purchase Agreement
from the Effective Time until the fifth anniversary of the Closing and (ii) be bound by and jointly and severally liable with MJB
for the performance of certain provisions of the Purchase Agreement. Dr. Byoungkwan Kim (&ldquo;Kim&rdquo;), MJB&rsquo;s principal
scientist, MJB and the Company entered into a letter agreement on the Effective Date (the &ldquo;Kim Letter Agreement&rdquo;) pursuant
to which Kim has agreed to a non-compete substantially similar to MJB&rsquo;s non-competition covenant in the Purchase Agreement
from the Effective Time until the second anniversary of the termination of Kim&rsquo;s employment with MJB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing is a
summary description of the material terms of the (i) Collaboration Agreement, (ii) License Agreement, (iii) Purchase Agreement,
(iv) Promissory Note, (v) Pledge Agreement, (vi) Security Agreement, (vii) Marks Letter Agreement and (viii) Kim Letter Agreement
and does not purport to be complete, and it is qualified in its entirety by reference to the full text of each of the above agreements
(i)-(viii), which the Company intends to file as exhibits to its Quarterly Report on Form 10-Q for the period ended March 31, 2015,
with confidential terms redacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 7.01 REGULATION FD DISCLOSURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 22, 2015, the Company issued
a press release announcing its entry into the Collaboration Agreement, License Agreement and Purchase Agreement. A copy of the
press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information contained in this press
release is being furnished and shall not be deemed to be &ldquo;filed&rdquo; for purposes of Section 18 of, or otherwise regarded
as filed under, the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), nor shall it be deemed incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(d) &nbsp;Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><B>Exhibit</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 89%; font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release, dated January 22, 2015.&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PHIBRO ANIMAL HEALTH CORPORATION</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Registrant</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: January 22, 2015</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 6%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:&nbsp;</FONT></TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid">/s/ Thomas G. Dagger</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title:</P></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Thomas G. Dagger</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">Senior Vice President, General Counsel </FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">and Corporate Secretary</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1500148_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-left: 0; margin-top: 6pt; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.1in"><B>Phibro Animal Health
Corporation Announces Entry into Collaboration Agreement,<BR>
 License Agreement and Intellectual Property Acquisition Agreement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">TEANECK, NJ, January 22, 2015 (GLOBE NEWSWIRE)
&ndash; Phibro Animal Health Corporation (&ldquo;Phibro&rdquo;) (NASDAQ:PAHC) today announced it has acquired exclusive North American
distribution rights for vaccines using MJ Biologicals, Inc.&rsquo;s (&ldquo;MJB&rdquo;) vaccine technologies focused on the swine
industry and additional vaccines that Phibro and MJB intend to develop, pursuant to a collaboration and distribution agreement.
In addition, Phibro has acquired exclusive development and distribution rights outside North America for vaccine products using
MJB technologies, pursuant to a technology license agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Phibro will also acquire certain intellectual
property and related assets associated with MJB&rsquo;s vaccine technologies pursuant to an intellectual property acquisition agreement
with an expected closing date in January 2021. Closing of the acquisition transaction is subject to certain customary conditions.
The collaboration and license agreements will remain in place until the closing of the acquisition. Phibro is making an initial
partial payment of the purchase price to MJB. The remainder of the purchase price will be calculated and paid at the closing of
the acquisition based in part upon the sales of certain products sold in the year prior to the closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&ldquo;We are very excited about combining
MJB&rsquo;s proprietary technology and experience with our technical and sales teams and our global expertise in developing innovative
vaccines. The MJB business broadens Phibro&rsquo;s U.S. swine product offering to include specialized vaccines. Our two companies
share similar values and a common vision of the opportunity to develop custom products and programs which fit the unique needs
of our customers. We believe this partnership is an ideal fit for Phibro,&rdquo; said Larry Miller, Phibro&rsquo;s President, Animal
Health.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Phibro Animal Health Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Phibro Animal Health Corporation
is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for
use in the production of poultry, swine, cattle, dairy and aquaculture, with annual sales in excess of $700 million. For further
information, please visit www.pahc.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 14%"><font style="font-family: Times New Roman, Times, Serif"><b>Contact:</b></font></td>
    <TD STYLE="width: 86%"><font style="font-family: Times New Roman, Times, Serif">Richard Johnson</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Times New Roman, Times, Serif">Chief Financial Officer</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Times New Roman, Times, Serif">201-329-7300</font></td></tr>
<tr style="vertical-align: top">
    <TD><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
    <TD STYLE="text-decoration: underline"><font style="font-family: Times New Roman, Times, Serif"><u>investor.relations@pahc.com</u></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.15pt; text-align: left"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I><U>Forward-Looking Statements:</U><B>
</B>This communication contains forward-looking statements, which reflect Phibro&rsquo;s current views with respect to business
plans or prospects, the transactions described herein, and other future events. You can identify forward-looking statements by
the fact that they do not relate strictly to historical or current facts. These statements may include words such as &ldquo;aim,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;forecast,&rdquo; &ldquo;outlook,&rdquo;
&ldquo;potential,&rdquo; &ldquo;project,&rdquo; &ldquo;projection,&rdquo; &ldquo;plan,&rdquo; &ldquo;intend,&rdquo; &ldquo;seek,&rdquo;
&ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo;
&ldquo;can,&rdquo; &ldquo;can have,&rdquo; &ldquo;likely,&rdquo; the negatives thereof and other words and terms of similar meaning
in connection with any discussion of the timing or nature of future operating or financial performance or other events. These
statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties.
If one or more of these risks or uncertainties materialize, or if management&rsquo;s underlying assumptions prove to be incorrect,
actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak
only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties
and other matters can be found in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, including in the sections
thereof captioned &ldquo;Forward-Looking Statements&rdquo; and &ldquo;Risk Factors.&rdquo; These filings and subsequent filings
are available online at <U>www.sec.gov</U>, <U>www.pahc.com</U>, or on request from Phibro.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0.@:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C8M8S`Q-"`W.2XQ-38W.3<L(#(P,30O,#@O,C`M
M,#DZ-3,Z,#(@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+R(@>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87`O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM<#I#<F5A
M=&]R5&]O;#TB36EC<F]S;V9TPJX@5V]R9"`R,#$P(B!X;7!-33I);G-T86YC
M94E$/2)X;7`N:6ED.CE$-$-&-4)!03%$-C$Q131!03)#1$8P-#$P03,P,C8V
M(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.CE$-$-&-4)"03%$-C$Q131!
M03)#1$8P-#$P03,P,C8V(CX@/&1C.F-R96%T;W(^(#QR9&8Z4V5Q/B`\<F1F
M.FQI/DME<FEA;FX@36%S=&5R<SPO<F1F.FQI/B`\+W)D9CI397$^(#PO9&,Z
M8W)E871O<CX@/'AM<$U-.D1E<FEV961&<F]M('-T4F5F.FEN<W1A;F-E240]
M(GAM<"YI:60Z.40T0T8U0CA!,40V,3%%-$%!,D-$1C`T,3!!,S`R-C8B('-T
M4F5F.F1O8W5M96YT240](GAM<"YD:60Z.40T0T8U0CE!,40V,3%%-$%!,D-$
M1C`T,3!!,S`R-C8B+SX@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@
M/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[0!(4&AO=&]S:&]P
M(#,N,``X0DE-!`0```````\<`5H``QLE1QP"```"``(`.$))300E```````0
M_.$?B<BWR7@O-&(T!UAWZ__N`"9!9&]B90!DP`````$#`!4$`P8*#0``$&<`
M`"4_```R\@``12K_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`@$!
M`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`__"`!$(`%P`IP,!$0`"$0$#$0'_Q`$1````!@,!`0``````
M````````!`4&!P@"`PD!"@$``04!`0$```````````````(#!`4&`0<($``!
M!`(!`P,$`@`'```````#`0($!0`&$1(3!Q`@%#`A(A4Q%B,S)"4F%P@1``$#
M`@0"!08'#`@'``````(!`P01!0`A$A,Q%$%182(&<8$R0B,5$)&A8G)#)"`P
M4H*2HC-3<X-$%K'!LL)C-(0'\-&CL].4-1(``0(#`P<*!0($!P```````0`"
M$1(#(3%1$$%A(C(3(R!Q@9&AL='A!!0P\,%",V*"\;+B0U)RHM)C)&03`0`!
M`P,#!`,!`0$```````$1`"$Q05%A<8&1$/"AL2#!T3#A\?_:``P#`0`"$0,1
M```![^````/#D=T4"!L711%F*F/:.O;=?',N*<D^0NS7WC:RY4T=K.NRNWY=
M3O3H````>',#E?,/0TX\IQ[/JHD^[>]F35W$B7M@Z+&2;=66;2VX$=C4T&'L
MK45^P]#(E[87%]5UTPZJWR.Y'=8G2GE!_%<(Q*2#<+U373ILKO+O0```````
M`#7SD*9"FICY-CI;T]M=CU[9FG%`&13PH&Q=':_TS4\1_:J&J.IAR57.JK2N
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M>,-QIU43E]\Z^9]*/?\`T:1[^Q38[5;<!G9NV%TI:"4=1U.<X`7F%(CR2:PP
MD/([Z!17%-M6Y!!>&HJ+^-XB]?LNWGW;7V9W$YASD$8RC9M3#E+26DJ:2TVJ
MZ```````E1FHWH*ZIGF65CB@KK)_16UGV[MY)KGLSH#PYB!1M$$8RCB;,567
M0FRA;F/J,AQ'BLI<5IG5<1I5<1\W$V?]O?V"W%^;<7Z````````!(C,QY1U]
M,_)\>U:Z*X9LC6GBM+=G[:WUC-YH5-]T`````'__V@`(`0$``04"]MGM>OU&
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M(`RF"!$F0U9W!]M+NE4A@AE!W+2$J!Z)M9J^3RG&?D>Q]/)=Q^^WZOV3=`ZC
MXA\/W?[5K)NX;;Y5II^O;ENFP6L/P5XBE'J=*T+7K';-LVJ#(UK;?.>U6%AK
MVD^,?(F]:]Y$\C7%J?R#XZ)X]'_YGV2YN]7>QA6;?3OUF\KKM)>E8,0G%S8I
MAJ^@B>-MGLLI*P-13^2W3/Z+X@\8@B;EN>C`VC;?)>HQ)%D77X57XJUJN733
MZSX]@[S;^2*>NL]JT.CC4NF[-H==K-K9Q"^5+W1=-K])I,\OB'V=.<XFAV[Y
M`8=?*%*%D^:R"#7]AD6>L:O:6LU:2YES*/5-EV*XGEV<_P#;(UP>5M9",$RE
MV:]LY+[FQD[7L6S%JIEI;R!;-;S+-VR7NRRJNUHW3WU&>6IHGKI<,@]&_G#O
M+JEC'D!E@>,9%DSQ?MIUL://'?0/ZWK5ZMK"UJYE6@8.Q"+EWMIHVPWUY6ZX
M>^EOK)TZ:\%G8;`!A[Z[6JKZ_P"-9QD1$2WN8=-$FR;#;;V/KXHNL9+B1YT<
MP[O2S4VP5EX*54U\P\F#%EX2EJRU_P"EK/B!",`05%;'.M!4.DRJ6KG--70S
MS%KX:SY%/6RB/B1RE$($0&R;Y7U#9]G<;7.TG2Q:X#U5$<EOHT621-DVG6UK
M-VUVTQKV/3WDFQ!9:;I2UC+W=;>U2KU^TV$\:HMM+?K-K9W$;CV<80(S-N=(
MI)A"ZQ9UCGVV\5N#\F2F.9Y%F/S^^6'#M]MEPFZW),E;+:DQ)LV:^!H^PV"U
M7C>IBO"`0!_1D_"Z9?Z?M6W]%^;_`,'P7Z;"_!R'_P!;\U'_`%AS'^'T>[__
MV@`(`0(``04"]LBRA1<-LX$PFR3G8^YLGXMA-=C9\]N):6K<;?6C<'L\I,%L
MT5V`L(<GZ,Z]B1,EVLZ5@($N4H-8D.P6MP&8RHK1XD*(W/C1L6'%7'54!^%U
M^"3#ZR1$/72HJQ;:7"2';1I:>Q5X2ZMR$="IILI(='"BY]D^DJ(N2::,7)=>
M>$^MNWB<US7M])[G-B5%(T2905\<D)\:H&6QIH3XU360W0)S$?,A=E)=A(IG
M1&5=>**]CU5$5<Z'YPO/9-P]C7MMJCXK::S<`GI]WG]*T78@/CPUEVUN'M?A
M$BU9F2(<,`GWELU"S)T@<6+%>V3%I(HQGF65?"D5]>(20+!)Z[)'"&2J(Y+2
M*M?,CR^[48C6J[([$(=UC&'AB*4M;T_.MK)70X<U8T6MEN0:'>6TDD^6DF>^
M$*N*\<6<9QID:<^2(;DJPSIA)ILVEJ=-4JK32E>P0"-(W&,ZU/':.3)$)F&"
MUAI4:.%B1D^*X2-BHG*FC`&WLC;%CQD*P8FK&$P?QP1VE$;H0N;.5JY4B5*?
M'JZM.Q[2,Y5,:Q>TP2.9V'_(D@[3Y(6C5\=4P,5'1P!)(0#4(QC.1L`O``]U
MY.H;LE2Q11E>>SF,@M'7843#,>DNI=%G1YC6E>Q&O<W$,1"=XG4JJJJ4CD[Y
M>EIB,Q"/1G<=T-*1J=3D1SN5GW0(R&D2K(U14M@,]?YR53C([Y]E`R/;P9&(
MJ+]!QA-R3;1(Z3+>5)R/"DSGU%/7PPR1#$[VN:UR2Z>(575TB.JR;B/B;`1%
M2]*N?NC8MU)QUO*7"6$E<[IC*&GG'R-011JUK6)]$G:X)\7ID_IN]_L^-^)C
MNS@OT&1?Z]C.WQ[O_]H`"`$#``$%`O:24`6/MAICK20N+.E+GR3KB2)"9\N8
MF)8RTQMJ9,9:B7!R0%^C(L!!PTR07!QS%QE41<;5QTQL.*W.P%,[0L[(<6)'
M7'UP'82K=A(Q18*88&`F"-[?XR=,<Y00CE0,``OJ%@B?AHSP+&G.:J*BIZ2%
M5`PX",])!'(3J,J".1'&*_N#7\'\]`VGZU*17?;V<IBHCDF0NTD&4K'>G\D]
M"KU$1S^@(5Y^[WE16O>Y?CA^S!M5[W)TOD/56L$0C2$5<(/MY%<JM_G)8EC&
M&;JAYPG..7AO;<N(G"%_RPB_-[.IY6??I1`M3HQHT(I417C;TL<-&JO^*X;$
M8F6R)Q$^\$O4C!N1R8OVQKN6M55Q%^S'.5>K\^?SQKG+G*];G<8J_DJKU.=P
MJ<\9:O3(;%2%B\Q2-<CDSG[\_?J3I:[E&KSB.Q7_`).<C<=]E7^5=CEX1/OZ
M%,P+7N?*.T"-C8YK7M5#0U"<9DX3.,X3CA/3A,Z4SA%SA,X^_">G\9(G#%CR
M%E/APTCI["PFN7Y$J/@YD<GT5>U,+,"-#3"EP0"G4$9(R-55]RHBX:$%V+&(
M/.[-'B63DQ+!ZY\XF?.+BS#+CI!%SK>_&0I#\%7";B-1$^B[HQW9X+\'K_T6
M)V<7HQGZ[!?K,;T>_P#_V@`(`0("!C\"Y/%J".&=0H,<[GL7##&]JMJD<RMJ
MOZUJU7K\CU>#^U<1C3V+C,<WM7!J-)^#)3XE;1=UKB/DIX"SS7`8XC'S4:[V
MMYK5Q)WE:M)JLI,Z@OQLZ@OQLZE;3MZ59,TK@.#NSQ7$:6_.-R#:DQ9IM'ST
MJ^#^3$KVWIW0IYU,!NZ>)^@4SAO*N)\%9\*!N1-'AU-%QYVW*9^I@X;/]*'I
M_6=:F;=E>6&!@AZGUEM<VPP\\F^]0QKBYUD<$V@^G2%9UP@GOIL#*K6QLT*F
M^O3:ZHZVU5/;,X(=9`)GN?P@VYTYGHZ8]P;!JP0-2DPN:RT]"-0-,D<+%8H0
M,5#.HRNAS*1XBTK>T;?289V:1H7M:YBS,5'(:3QPP`<M*GGE[T/65#QVC&Y'
MT?I3/7J667"*MV*;.X(5:;-VTDV+U%5H$C!VE>E](T"U\QZ/DI]:H(L`NQ3'
MRP8YNRO4O:.'O)1T(-K"->&87+W54`^HJ:W-',%4E;"FQT.=-?2$"]MJE=<I
M&;&TSP3J^%)W8,F]^XC(QCK&EP5A!`&8M\4ZH<Y5,OV0Z/5SI]-LDKK+[>],
MI#=P:W$?[E5J1:'57DWB/>C5+_QLL,1XKVE2I&-MXS=*EGUH0`!'T*'$`+C$
MVM\4ZH3&WN6H_-B!WE2SP;&-X/<5O'QAFR4G?=$KU&`94_E*WE.]MO1G[%%F
MSDAF6[9;3@#T0B@ZEL/M'AUH46BX";O*>]D=L2\T(GIN3ZI_*V%F@IM2'$<3
MU!0%ZJ$?9*/W9T*KQ&HZ/4/-.+MJ0EO0GU7"+H@-^J=6J"X@#G_@@7;;Z@:W
MZ_1.%/8CD92^Y>JJFYS'_P`N3_S.N\.C-B$'LM:58O<5"98RC%/K1X;.NU-I
MQ,SX<]N*%%KB7'-W=84K'S/F@GTPXG=MMPYE[EY+1$]@^IL3[3``GG(3YW.E
M:W^`Z2GU9G!K+!TYE3;,9JN;!&@YT,,)LW6I`3$=ASY#4J&P+5&N\V!>Q;GI
MEO6,AIU!%A4]/B>E^>HZ;CG4:1UL,X4H.JK%O8\1!\=9MRF-ZE)L4D=6$.A"
M4P@BP;)O6[^R,5!I4!BB]]ZEIVU$&").8+>5+?4GLT<G>^E.[K*7UC-Y3QSJ
M`?*_`V*(N^!:0K3:M7AT<2H4&DC.\IL3QRZ#G:,4&TW3ZM^GE0<OQ](^?HO^
ME5=S1\5%[8CF*E>"'?/,K!V>:N_TJS^3S7]SJAXJTAO^9WT"E#ZE1V#&_4J,
M@I-Q=:Y3UR:E32I6"#?A<2"LGA^F9&._GSQ\[5]ZX7N.B9<3WD/G%<;??N\E
MP=U']7]2X<(:.7__V@`(`0,"!C\"Y.NX17#:2M6`6VMLJQSEM%7]BUF@K7!"
MU'#X,K=9ZUC!N`6HTE<1P"UHE6,"V6]2V6]2V0ME61"X9BM80^<5!T9>M8'D
MQ6ZIF#<ZB-5N)43K.T_$BS5=V=2B=72+O);NNHB[*87P6]K6U.[)!I4P)@H&
MT(RFQ"8VHR[2B\ZJL)O4,_)@ZY3L_#W+<U+LI:=F&4E2#94[]D+22H$Q31G3
MGZ%*+T1G31G@K-E2#9"&)4#F4#<I6[-X1J8,/=DFSY"<D$8(%$VH#`*&)4X&
M2Y05H5R@,C#G530'=RF;F5EV6)O5MX44`<$!F4,V0:5`7+I0"E"T`*V_(UF=
M57X@]V3_`(BIFW9)0@,Y4<%,5$A`XJ49++T`CH4RCDF<K-HKVX_PPR2NN46Z
MU%:E^&6&90RQR14<^70H-M<H7J9WY3R9Z6J]0KMF;BKX'3\&TJ]6:K%PQTE:
MMKH*WE6K97`>>9:P4#>OGQ7DO+S7W=RM('.5"+G'](6S(--ZC4UG*`N^%K*R
M;HBO[D5]RU-YVK6WRU]YTK4EZ?-:L(<O_]H`"`$!`08_`ON52;<HXN)GLMEN
MO+Y`"JX(;?;I,E?5<>(6&U\HYN87EFH,).QM9"_&XJ8[UY?:KT,(#*?(BX[U
MYG&O[?\`Y8HU=[B-5X([T^=%Q_\`4G%^T0#_`*L=Z2R[V.PA5?C3")*MT)].
ME1)QD_,F8X09T*9#ZS'3(#X@[^$Y&Y1G3_5*:`ZGE`Z+7[R<>,OO2<.6U')-
MALNIU_,>/0-5P22IJP(Q>C#B59RZ-6E=XLNM41<5M]NE/B7UY#MM+VJ^Y1NO
MGPA7*X1X:?JV!62ZG8OZ-OXE7"+).;-+IUNHTVOXC8ZD_*Q[.S157K<W7?\`
MN.$F.Y:+:G^C87^D%Q_\RW_^G'_\>,[7`\T5H?E$4Q4K8`EUM.R&_D%W3A=M
M9<<NA1-LQ3S$UK7\K%;?*8DTZ'-45TNSZYLE\XXK*C/QM*Y.N`J-(O6,MI38
M3\I,,M2>:<CI1-3Q\ZPXG6!%I)%IU.+Y,(B.@P_E4%+N5\I()A^,B5Z/N2,O
M1`5):(JK1$KDB9JN%M5MDE'C)5):-+1URO!IQU%R[03SUP#S;(VV*7\9,U(Z
M:+ZS#/IT_)P+CK/O.9Q61,1#%"_PV/T8Y^5<((B@BF2(*41/,GWI1,1,5R42
M1"14[47#AP*VF0==7+B)0WEZI$$ZL&E>I$7&Z^"V]=7V>Y0U<.VNKU.<78)%
MVU##=KON5:"S(RVS1>"B7H)7HIW%[,"ZT:&V:5$D_P",E^&X&PYLN<N:([TC
M453NTSUDJT3M7#5VOC:2+@[1YJ*YWFXFKO(3B%^DDKV\/@:LWAZ_W&U,6ZTQ
MDF-07]H7)DHCDZW,EJ21W`3%PO\`"\0>*9-GM)(-QGMRZLQ%5$+VN5:(BYKT
M8L\.Z7B5?K5<KA%@2XEQ)'G`"6Z+.]%>HAM.-$>KJ*E,>(H=B\4W:V6NW/-0
MFHD*3MLBY&CMA*73I7OK(0JX\,)XFO(.WF1:HTF8_<YC(RGW9`[FI=T@4LB3
M%[#PT0I>I,$V+8]S341&WY%`!\)+B[8*TA:D7LQ;9OC'Q#*<\/0`E2IS7\P1
M9P/:(YBTV['9[RMZSU?BXE-6WQ=?HL:XWXH\*'&E4;88>F[`-,@@+00#AB);
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M2''73P1//ACQGXL@/V>Q>'Q*[,,305F7<)<05>C_`&<Z.,Q63'61$G>I1,:6
MZ<]XDOQ*BDFH1=N$Q2(R3I!I#55[$Q-L]RO[WB23$C02.X/"36A76$+EFV-9
M@P$>E$0:)C_;FU29TGG;Q+?E*2O.)(]UP#D[(F[JW"07C;\U,?[J>,94F0XD
M2R!98)O/NN:),Y#`]&X:IJU2&L6:R6V6L&;*?5WW@E2*$+0JX]+%$5%4V^CA
MGB\P`NS\^;:+D;0WE''&Y+[S>ES?W-PW0<U%^$N>/]KH4J2ZEP=\-,WVYT)6
MR=>G1X[+3KB"J=XE9-?/B7+LLX8UA?E[;HR[DZP,YZ,NVZ0MCJUI%^?0:X8\
M*6F?)A>&O#K#%ECQHK[C*W&3"`8LJ;+<!1-Q'9(EI"NE!Z\>&#DW-)5QOMM]
MY28X,[)6USV:HTCNXIO9G35W<QQ=X%TDO36K+<6V(,F09.NBR^P+RQC=-5-S
M:)>[7@.";<%#;<%0,"2HD))115%XHJ8./'51CZDGVIS]6!'79KTHTZ/Q>7$N
MY)WECV>:\HUSJS#=<VZ\:BHTK\'."GM'6&VE7_#`C,4IUHIK\%ZG1V79$B+;
M)KS###9.O.O!'-6FVFP12,S/@B8;)Z++A/S']!,S+3?$>;)][1K=-NVN,HG?
MK75PXXM=L:;!!@0(L5*"E*LLB)*F7228\2,P$-9DRW.V]C;:D/D)3OLVK;B-
M/OT`7*Y"M,6.XR@O"2K4T_/=YB'*CV\I(,[%`*5:XU4U/U%->K+%]N[[?BA'
M+G='-.W;INR#:FC+:-J5D.C8I\Y<NG'A6UK#N\J+X2\/Q(3++-OF2(3YO("O
M[Q1[8\)F2L(I:33#%K9L;NCQ%>BE3(3-MN)KH854$I#`0R?;RCMTU".#\7VS
MPWRZP=RW&\=KNJ.MK.:](8_N_F#;HF9H*BB\<.22L[:L.2EF76XRX<^+KW75
M==V>;B1E?==)?5R'$S7X>DR6;9&BVN(0V>[O-C&B,I1MDV;>XT38F2TTJN+3
M:V(PQ`.&3KC`@;>AV95QVH&@&A5/.J(N'AN%@;/5*<E1Y4>WW*:P^!/JZ!$<
M2#($#SS$EKAJ25AYJ2$5N&PDF%=(D2+':U%19,RW,MHBN$JKQ7/`VR$RPTZ\
MXLJ><<5$'I1HB*J(JJNEL4TIV)\%E>^MW)3?E!1:)?B5,>)<^ZQ;[XU3Z<%Y
MU/[6"E1E77$,9!@G!U@%^T-JGK>QJJ=N%-DD)M5U!1>"'WM*]2@JT^!7513<
M)=N.P&;LA\O0:;&J:E7^C'O*:K<>X-R)UMD:0T`U<(TYVWHB-.+6F\*+1>*8
ME1[P\(S+#N0+OIC(Q&ERM6\S<(Q+FD9V(O!,D7$V\R9#>B7.G!9@T-MZ([<@
MX,%LE3],<B0TI(O2))BQ09IQQ5FRSY7B%4B[+LF<W.Y"(4=LO\O$(X[RY>E3
MJQ9[0TVBVFY,W1I)B@M';C`;%]09>KH5M`RZ]6+E;AE-#;[9!AMDSI#<D72;
MO/4;=].D6+'[X_/3!NND@-M@3CADM$$`341*O4B)CPPRX0`-\=O%U>JRPJA8
M8V4&.0)F#CRKZ?'$JTP7VV+9;F;<R^8C%5?>$LW'R;07/:.($1A1)!]%31<6
MEJ*".QEO4*!>G]"F$5J>VZW';0Q6C<A9)-*M?57%DM,:2RQ'6/,N%YW!`B6,
MFEB`TV1Y@3\JO#.B8M%EMT\&1E1IDVX-E%8?6/!BM*VVZVKGUCT]YL<_5KB0
MRP0'`L7AF=>[X""P+ANGW;6`$7HDXL5]5%.*Z<6YRYN`]/=B,NRC;;%H%==%
M#5!;'(4&OP6Z$F;H&;OT10:+Y-2E^;CQ=,+4@28%V%M/55&K<Z!%3Z28HN:+
MQQ5`,[5+/V.G@W7,HR]3K/U?X;>7%,-R(YBXTZ.H#%:HN`5QL#5LM;:F`DK9
M\-051=)47BF"\.6^%$60$$;S-<?``B1FWWWF8KB@(*K\I^1'->Q!JJ\,6:RC
M&8=N-Y"2Y)=SY./&AM:GW2[NIXG*Z6Q^.B8N]RY*/R]@=N#2-"T/)O/VOOBY
M#%`]$G<DHE4<1:8G7N9`A0X[#(H-Q87].VQ&1VX-ENM-2&V[?+W&^]QT5P$N
M=X?9MT)FW>\VI(-$B,ONFXKD9@'6&C,^6%'%<;RSIQQ8+FY:XS">)[B]%@`#
M8+<0;V))MS'S$,U<8C:C2O<;7->C'\M0H$:XON1(+NP\9AS)2Y9M2HVM6BC"
ML2W`KY(:U)*)3/%G'DXQ/2IT*V:@%IE8$&6X3:NH6FJ-"XGH)QQ9P@6^UO3+
MO<AB-[X[4C<T*[+EBXVR2KRMO:<-<ZE2F+!:.0MTB7>"DS+FNGN,,6UEK>FM
MU:J\X,EYH`UT7O=F/$<OW?#Y?PLD89,N6`;\R0302-F*NA2`&1<TH2\7."4S
MQ%OT:UA*-6X\F>CB(W.BV2@O3W040-QQV(TM4:X$66')KD:`ZW/4MMT&@=29
M!$OLIO$8>U0P[R<4SPB(B(B9(B9(B)T(G0F'I4IU`%H-2_W4IQ4S7T4XKBK+
M9'(FN[45C]4U5=*$O0@IWC7RX/PZT5$<MDB";G6[*CFTX[YR.OP.193:.L.I
M0Q7Y"%>(F*YHO1@WXPG<[,95<#@H_M:)[%]$^L3N'ZU,:X3_`+44]K$=]G*9
M^FTN:C\X:BO7A)3\>LA&DCJ\!FTX<<7-X6'2:(5=9%W-!*J55>O#2O-5)C6C
M+@D3;K2.#H<1MQM1,!,,EZTP-I*&U[N!048H5;:JV[O"M`5*KO=Y>M>.)T%(
M@##N1ON38X*0MOG*_P`RJH*I3F/7IZ55KQPW':'2RRV+38<4%L!TB&=<D%*8
M;DM10%YD70CEF21A?+4\,825181U?2TTK@IA0FUE'-9N*OJI[G.L,%%:D"6J
MHD$8E#+U<L20EQ`D#+<CO2!=4B1QR+18Y45<MI4RIB'/>90Y<#>Y-Y5*K&^"
MM/*"5I5QM:*O5@;HK*+.",40'ZE48YFCAM"E=*(1BBKY,&[(B-NJX;+KPE7:
M?<CTV#D,UVWR:IEJ1:4PK[C>LUCG%74JJ"L.*A&VK=="H2CU8;89!N/&C-"T
MTV"(VTRRT*"`"F0@`"F"9BF,B3FFM.\`+\P?K2_-[<-QQ%Z0;CGL(H5+O+EN
MNKP4NU<A3ACFI6EZ[/A1QSB,8%^I9_K7I^X421%1<E14JBIU*B\<<[:'BM4\
M>\"M*0M:^-1T4-FJ]62XV;[`6Y10R28UD\J='M03:=7RHBX0`G#&D+_#3/8.
M5[%7N+\>-0D)"O!1)%1?.F7WCVDAI.S6BK\E<*IR$,^@!S)?(*8+9I;8'0_)
M721_LFDHI*ODQHMT9YP2+V]TF)I%$]90KD"?+BXC9K?&NCC5C=GMO%'>YB7/
M%T&FX`OZM`[FK51.A,3)-SM3UG(9[C,6'(&DA(@M,DVX_FHJX9D7#).'W2BX
M"&)9*B]/EZ\(ONTDU(NJ0QI';7H3;!4//K0%P/N"]RT5/X1V2&2?-&632_$.
M-4B,;S8\2%B0)K^]4297S85M]IQMP<B$D!U47M0MG'=;5?\`2L_W9:X_1:%[
M8)K7_J98[JZ?HVM#_M2QQ1%N9]K41N&'Y2[^%W)$>.2^M<;F+BI^YCN`X2_B
MX1D)URN3A5HQ9X!M(OS=YX6RT^9<(26]FRM+_$7!U9<^GD-.XOXF!D7)QZ[2
M4IG()=I.Q!_!^+`M,M@RV/H@V*"*>9/O7VK8T_XFGY.G![?O+3T^[^=_-V\L
M.[G\Q\QJ]MO;7I?/YG[17&7/]E=>JOXF/L?\R?N.=^2F/M7\\;?3IU4I^_PG
M/_S#7UN?U4\_*YX'D?=&O*G.ZM=?]=TX'E.7T4[NQMZ=/9HRI]W_`/_:``@!
M`0,!/R'\%`50"ZN`W72HT6LOG.IX/3PR2P%(R[,0TZ)/:D6`_10LJ>[T4ST!
M6H_)3.ZM%L0VON-40`,HW6-*VH6J<-SK3:5B.1W%L[5"E@+-;2%\*D>^/RDI
MR;`$JZ!E="F;.65LV3%B!ZA5V%E+.DF9R=L5,VDLM.56[K3Q-"[G%4'FD*#X
MNZ\TI"QC55Z_05$V'#.\JJU%@Q6!2^S)>2KG&U2>%\*GA\R<:22&B%?).*`/
M?2H@P!F`65:=VI$;0-=OM`$Y6UZ"1DTN(V+]JHZ$]ZE0Z>DM2[9'$E#818+M
M`T62I9-TS:F%2'^,ADZ"0&N6[1BY1G3)BMX*<M!R0"F,```?C'XB4-5DR`1&
MFR#4EDL(FKO)T,Z%F+JJN;((HP871@1+RRT+V:#]A&1-G8U&YZP5R4(9,\'1
MW;%Z@.<W?5KR5L?-``````%@#`!8"K!-\\,'0T!2C:I2"*(+0$E0C=@(6!&`
MO<+-!J&UU^%M9K#!,&DIHA!2A74HG*L7D163NER^B-)P4A^:FJE2B1I4"`*#
MVBTY"M:L0WE0'!I5TI8.W/%2DU/^UH>%ZS%2KZ%!;8U&*2*/$]C(@S3.(2"&
M3,M=PJ,JY/=C=T/)"-FM.;GHY-H]%?5Q,<I+"'4B4V])B[@N]"[40!<,(U.U
M!#QI#-.@;/@IH0B>5X3@B(D5&4[-@)&B2U2L+NZ!-LS:2\#2(UIMVPP0ETL%
M$BA"+805MKVJ$B.0L3,9`W,E'@%%_M49O`;TBT>CZ"6#N=0W":,32).4"UZ/
M"+@:4M#*\RLTGJ@Z"[HRBF@HU6?>[/%LC(%&/Q4V2H(4$37Y+S+R`B6PFA!,
ML**#]AKT0I&(MTM@>AC13Z_8FH`56AK9,$TAK93(4,3PS@Q('/>L1:RQ,I$4
MVR6U2BY#`!!E4:R&AV@@8G5#R*&5E..(59%MQ@+@H'M:!=W_``&?MI0"/[I9
M*"2$4T<]ZXA:<$H&5M%2).XV[?X9\T:!A;<3WL)#0H&](HBUCL@.]%EENA2/
M5==A%JAWQU:`0'HEHR)W40/`HZT-KX4CQ1K?:]K"CO<)M*E[I`44C/D`AU]`
MY>,"3>Q1+&`M-A\BPLB8XRT*X!@]@]""-`9I\^[ZXN!4MPZ/>/`)NT46Z+90
MG>1`,AMUD".U,V-+K,QS0+2S4KUP#.BEEJ#8MWD,QN:^M.I``#W=<!DQ3P[7
M;FG5Y8YZNA1YCI2TN>B[1_W@T,568*D1.J:/=:!@8:LOS*$4M$[>C$B5",)/
MJ#ARJ8-`:PF,)DO2`0`($D1LB.1*R*NW2'9S++8S#1A6`A/)A&R9&K,#0$,M
MDX6&*7;7NU=@#`M`LES#4C=5MBW*W7*LNYDU(0I&C#)*F:HH8H8G"0:`31EI
MP<W(GD6SM([ERL&@I16&X(PS7.J1.N*#I-#&%ISD#",3634@($AIQ$776HN\
M,,GP*E(<:V%75."JJ2L4"`:FEN@1(!W&:$MVBJXUX-C!%`F<``$`+`:4T*>N
MDV,:!&Y3,KS7#@B1=P9548K9(6+Y7Z/G_P"[(T$+HJ9.^,)RR#&!8L5ZARB,
M54$RLJVQ*"2G9M9RQBFPNI8(V"E=1-$,E$;`T`#%4$SOR6MEDJ'/4RMB2250
M_974DOJ3+M*57-.(F1EW*9XUT=L290O13@CD]V`QL(%J#"XW-8'<25)2NC:V
MGH=HE1M5B@<%@("S-D&U$2GK;ZH23,J,V"2PG`\"P!4-LZ(FX,^,'=BKE(#E
M>1H@-XK2!5C$A&4+-_G]"34)1@'1REF0`U-P+?Z7#1<9[A15X$7B5*@W>5:8
MCL&$]4E,=:`1Y(G<(K\VUVQNV/+6?>%A8N'"C*0U5V3+0](K)$)!A.;1)WJ*
MG4X^V!M<!+UI0$@88S,X`E2/#U,LKF+2:A_!!Z#GQ"3#;8X;5=2YO]3L@^M2
M]1J8:*,;4:&$BTU/@A29>@`-((K!"X7.XL_/%-ZBY!AUF2-U6[HV^VDZ4QA6
MIG@G-2`$<C-3B16/CR1'(=\BM>1DL"RA!N!UK8T&@URKM*`CN!\+6$)YS4?X
MWOW/RSZ5U<\_7<=*YMM=[A>FXRR>";)FK9D[/UYJZ^XR<*_N1J/O$R1^NN(?
MQKC=OS__V@`(`0(#`3\A_&Q%VK^!4NDWL>,UCQZ?M7T1"D+II9B]ZU^ZPUER
M<BK&?Q*I^.3P^+UV\,P^'_%1M&F!Y_0EJ7)#WOZ2KV5J(/*WS0<-V$_T?-71
M<A@\']K[Q2_;7NK>*]S?JLEXM/2!P1]-"7]8/ZGYJ3=2E_I\E3"*U2W8S\JZ
ML!3=/^+I4>AM3;])W#\0;$%3`;7+POV'>@9TZ[\GU4-W0^,/W0!%A_D#"-#;
MN_\`47?#4;)SEKZZKR5@STT/?'ZZ4:>7ZW/CO_.="AZQ#N3WW^E8Q2=+9";+
M?<URU!#TI.2`V83":C0D:4B6[;XBD&!(&@"IAJ)AL-(YQ1H"B3A>\+4R&*&4
ME+0(S270*LY7I5PN'#6@/"HODC^4F%9(XJ4)GOE]AO**3#N'OXY*DC9Z*&$/
MUETXB?\`SUV1%>MS\M'FLB3$-8WJ".XMP6-]5Q;%++_@_LH)]B+X<SK/-1B0
M,6M3\30]F(#'_BEII'4P4I3-80&V(^*`U!]%*GR5&M+(6#CSQ3U+*4F-QL09
M<T:V2LSUQITO0O)@%B1B8YIZ`LA*66Y2;"_1]WH0[K/*QVQZ1!@G8E_?HE0`
M5L!-YJ>,SH5C2U^*?YEWRT+3C*X;M0:4^LL$!A,Z/;:E_P"LV]),ZB@(Q$G?
M:A!3`FOLV:N&@/"86[M[)XS0\*$D,$$R0'-0ZC6JZY9#4X[:/&%!%]"*BT:%
M/1,DA2O"U(9`B6AZ<'GM:@;1O*4LFG$;C#Y=ZEU.COIV]&C6U.@;U>0@>4,N
ME1!PW90PKDHUB>Z1V(&.U$=<%\AD-[NBI=WGPL7/=J7BR6T1CE;=*0KB:D64
MC=RR[;4(`IF=CH7:[4PL0#=A/:)[TX3N!E=BBN5N!)3,=@U*$9XQ_,_*B4H4
M&MCT5/!7WU_5396#LRLV<5)P5>S^OH,E/F"LT2))-9>UIE`+T`3S2T0A!J58
MXY:<.E3-A_+XJ0[,])8P4P-MZD_24G(:L+K:'K5JTGN%G1;;M1PDI-+@YGA4
MK<U78=>:5"SK7/)J!\T5O%RK85[6%8I^:D#`F)>L>*E1$IN8#HM="H('1F.!
MMM6:#D![[NAK4[9B;1IXR]Z9)`@\L+Y?2#L+GO6EX*MS^^P85BC9=NL?LDYK
M5N3&;XDG#&M2\[.=9J"'+77$?5JR]$2VC'C2G>2S3E$XGF,3O'-!P.+CR93S
M?K3R9%".<^:9>(X;Q<J&_?8YWJ7``0XG,.D\43-!=WI$$JZORM,G-[0Z;_7-
M%DIL[[O]P:59F>[LV?M_!`0W*ED/$6)[7.U#;=T_L6?$T_&ZJ_GS0D@_X/V.
MJ5B[:(?W3H:U.`'_`(=ONIY@Z$T2@R!B@UBY&+G'Y0H$:D\KY@MV+^%02_WG
M^?JKLCX'S$5'@.C37SMK9O#N_M+RCI*MC)=#5D>XWY!^*)F#5'T?33T&M3[L
M>*!>,GBCX`T+?Y<!YJ\]ZXKF/H9YJRW=_P!5:](*ZWU5P_L*6WQT?'Y__]H`
M"`$#`P$_(?Q\>&6K1U"U8U\]9E'2U.5Y:LWE4?N=9,/6G\2JLWR]90.VO^$U
M)=',=VOH>/\`M)VC?3S5_P"@W:S9^L%?U`T87B5_X"EL^,K/B>%_M:L*&6/@
M_LI>]R_XM\T62.5C[ZT)9]OO-3^"PE@KIA#/1?U4*O(=BK><O\4$6,?Y()#<
MJ0NVV77"HNRTS?W]*-]I]_\`E9$>I-<:E%!R7!^V[Z3Z`%#L#S0%)76AD@:0
MT[K73*U&%@YI>"&@C(I(9J3<KG2M.2:>$+TJ0E=9KS..*EQ+PU;.GI<G8$]>
MJ5#A7<59J+GH`YF#6BK;OJFON(4`2%K33$AS2"W&IX\MZ?EBUUK/LA/2E]V5
M(#(J_B0\=JY='A>@D.1'I`&0HSK+P_RB/:5*#)(HQDR>]J-G)V_Y0,)CW:58
MIY*F:*V'^5.8M-VMD"V'^4`G:O[,H7LN_P#/59S#?U3>"ODT]57]37XJ5>DH
M32=$=ZM',IUO5M75P5.#G/DH:I6'S4Q=I0<GM4VBQYIV1BQIPN-:B4R4L1J'
M]5:[7HC8,TQL?#?HY$2EOYVTW.E!TE^B+0F)I91+F-I?%30`;_?BG-@1-:!E
MWIB%+%(EKK%**!)]_%*(I+GM02H(K9A_Y4!A?T8O8*DQNP&Q[S2K47<EWT='
M+J]Y'W.SSAUJ7+DLG:EF7-(<UIM+3"S6"-*"9"]7;+S-.89I1%DJ%!;-03.M
M6&PHF?V?/U1TREL?MK,</'!^'#4\>GC_`)4VT-&?.&K:<6RA&YC_``P95Q74
M=YK^BH6B.:DT35;NU%J(O^,4+`DI'['O]4OY!_L4W*)T?O%)0IY?RL`?!2QB
MCIU63XG_`%66#VV/Y0B.T0?+3LPW+O;M2,SS8J)(</\`*QCWKB%%Q/+/_;^E
M_P`2G3_>]=6]M*ZS18^)^?\`_]H`#`,!``(1`Q$``!```Y"K(7,@``W=6E_3
MC!LAZNM)+))1=9))1D43DQDE=10D'<:J\#2;(T,T1G3L)&%$$XN'*^59H1Q>
M>>"]48Y.&EL_.E@!M5LFY)))(7/X`K;!N7CM(````6J[4D``#__:``@!`0,!
M/Q#\!@`H``E18`9:EO&#*9'I.T,,U&F0U&J5FMIHT6`&C(0(CK@TNYL+1T1'
M=5\\;"%PN58[<=*8+ABV8J,8_9J:0:E12'C],B'<E28&&Y\D+Q5$I@@R!'`K
MK**(T=Z>G^(2T$$2!*T1N(X2'3\DM;\7J,D6)`2%"@`9:!$3T$@`#226H(JB
MEQ;HL1D-'%7,GV=7;C*2.:C%^-#<;\T&BU/"'LI!%I*U`;@.6X9\"AI3&P,8
M9R]Z5"22%@D1C3(T^.9FLD86QLTNO+'$!%^%E1>I*V9%!:(7>K0U<==9F8E*
MBM=`00BR")>8*#@QSQ#5>T%EDD4W7RVI@`M2`MA9TJ"*B1$1'"6$>]"9\L9C
M./1;@V/VTN)036F*8)2P33MN90N54DM)1J01)CU/^(RRF40J=\),>&E!>/+2
MZ%!,P*!A!8BD3(G6H=GQZRV?#4.SX_`N81#8-L,(EZMGK&^),L:-#0CKF?0<
M)\2I&;)HG<*71(HB1D7!``$-)#(97:`A"4*6&SDTO^_2(4\:-0@M9)<*$BR6
M!6D0,XJ`94"9S@=`P`(`L%(^]$:<+AIBA-_I^W+`Y`,Q-111)PKDD=P2HA5"
MO`)'#X-*ER!(?+BBX8+5'SW2LO/"EA)*4O(FYZ`73AA+<H'R5'BT*@+"F@KU
MSO6+.38J-QH)11A`L%8I=\!A<+J?%%`!=`A6B!N&ITVM',&!T7`K6$S4,+^8
MQ&MP'4:"YR"4F-<!";(32\D554XL&%G+\>-_>.M>=O1[!9N[SV>Z)>=9O4`M
M`K;`IV"I&!AJ#_+<BUZGSE!D,7B!4%E)@"K"1*@N,@?*TL@2Y$(888*A#GQ;
MY],2`2R5>/21LYA#CM+%'%5#U/<Q1`EBE2:DST*^I)[A#?AD0H(-"0I5=S;S
M`$W."&(!I1>$?P,TF6T)W4#R0?G*;Y`,1:)P]\Q>,S7-0AIR7CBX]X*)JQ06
M(RWFRM$1$::7J)F6#!%W)DD]W4*XAR=<I3-,@I>!?!6298TZK,9+WCT)A4XY
M=L,00489A@$P0AK/06#$<ZV#Q>#AU7H3:U&XT<$`6`42^E25;H#9)L6(`%8)
M*`,<Y%U$+2$!+RL?=S@ND$Y24M1#@0M)8?='4S1E$3!_0CK`>@[8`"=!E8_H
MKY.Z2M0D^.P-;])=,4IV5A!N)P$P,0O38Y4JFA`RL!`IF9@<;1-1208)CT:H
M!67-$S=#$HUIPA-.;ESD1Q4F*OJSBLPG>>8J/#SA"_38&B%AZ2@WG"R0X*G"
M"ENT\[U`$B"ZC-!&9VD`3TA8MBEO<XN!(BH5+4VM)ZY"#YKR7)GC'0AQ]G38
M414P_#A'@H!I@D5)QE8],@X&@4>_@6=*[S4H/"H.I$(RUB"(^:65BMJ&S,$7
M%X^2HC\4E?3M)#-2*G=FWKO&DL2*(W$%;+D&;<1#-I_7]R4S0S<W?27+F"F0
M9&&=A4Z4OH_UL-#,4=D"P]"$0A&@MH@Y(!A`4$A)8M/MEKF@RB`(@B4.WIX!
MBQ`)*28:NB/>/V<O9ISJ-]EFR'A8@=$2$>Q?YK+=K7HJPSUQLV[!3Q`IP>W%
M\4TY18(H%AMT"86G7HJP)B4,O%DU;%!I-IXA@LEY/T"ZZ(WD5V\RQ`,3J:>I
M)*?6A\?BJ7J@1R7N0O/,J@O!C&?MYL,2CP7,R7YCDJ/6B`!_."(2```8HE6$
MKKL*X*5V(FFFET,*3O<4S$104#Y`!HP]KO1%LRX1$BH2+A2(E3,`U5P.Q%90
MU&3>%3M`B%$H2*32:(TV7CHPM`N[`.$67_%<@E2<K#Q-CBBJS!6Y7!F+!P_C
M.$5)>'%[$&0)LBD9:G.>?6HCU)"E/-,/SJ0RB5L;:0W]2S;73(2+4B3*^'9!
M8Q39"RP'C]WU+T#*%A4B"X@%`138!A$]&B3[LM6B")BU!P[3',GIH<6"K(R@
M)<$1_).8Y:.HKI#)&P"M%,*2)4P()82NDI%BWH/!W/V4YF-SW)066B:H,*81
M$:OU3`J=RLW8<!2$V4BL@/!!S$LTS)!*`MM)H#.U`+`G1<3ZFRU#$PQOIY_*
MPV`E2`-6`"K?<(G,R<76*DUT,N%IC+J+&I0-#EH>CG[:ABP,F-<K&.FU"<N+
M^.`LBCRYH:6]N^+CFP!DDL9NQ;8='U4R4[7S_:</$&'$8M%U%M3J)'V%1^+P
MOJ4M$T7<R;Y(@KI0H>]V28Y#=LI<7;3^9*CHI3I&$()"+CPIW4]F`=P;&SF2
M@:TR)2PRYJ)=#A`262&"*78;U`*A%G02!S3.E,4X"1.3!B9B\M,7%>"DD(RB
MAQ0>C*=5RAP00B;4.:A1P%TP$J5JM`(S;EST_P`?^@K[3*N4.NV]AU_]O">,
MZHQ7[8B,>$QKBO$S71_[>E<U.ZIZ#XKE#\FZ[.M<Z>5#;W^5?J6\/CC#\__:
M``@!`@,!/Q#\%`EQ4X*DR3=)&F]#S'>N^-/HKQ"?F-.J*Z`?IJ6-O;!6?DX,
MWN5=H!M_13L'-&3W+TB:G*[0N>:,,]1'BP=JBQD9@>L#-<F/S8"7%./C3]%?
M,V8#4*>0Q)[-)AEV#M4T6-1\L/V4"0M0/#^A46:DPOV)*#7#O^_%#0'W995.
M1:K#I%=A^@KGEGQHGQ3Y880!V9J3,A-I'8U7J-&&"LPGI)#N6DT)!,%W3",:
MB-V*(C5%DZI(P7CB:LDF/PGHG+`K`38+KP7:;D4@MVCMM\+"=(YQ9PG+H.<]
MVA($NF`?!APH\J-$#@"`['^2E`(1!'J-2YS9B+=8$Y0Y*-/&YIZ&J:CLA%$7
M"@MP-A,$Z(SQ>K1@SR)[L[FGK'BRWDB87DQ!=4B]#-ZQ0$O75LK9H`0("K^$
ML@)$V(JAI!+ZF-670UH\4OP5-"`1N3)BIU/10=OG!:IZ"&!F(L(7'6@3*>XE
MU1ND)'-3C)4Y%5E,$=Z+=R9L@2<K2;/`!"H#$`%B^*=5IF"QXI!NF%QC8B7M
M7,F+&9VC,TSDXS-N-YH;_$<4-D1H4B2*Y=7,F7!Q45=S-)!9'<+\A&Q6O%LS
MI&_HCH)89@PZI7$RD>C-JE(@,V+[BG`P1S;+8ORO:IA8'I-AV$P%DK$`Z9OB
MRP@-F`'+1A>QB4I.`J<K)Y:L@U0,68(@D3C66FB"@"8TF`M'!0`RI;"4*M@=
M;-M&C)^2$R2V"(+66<4QW*0(!B9L0=J?/+I"]"L1WF,T/\YTDF(DD8)-K1=-
MTZX!>5",)NL2G$4'$0"`"&8RWID#D$B-D1R)3+,+F0RU#2+V"<JE"72;S=F9
M1=N4XJ*[(7D`C<5Z,!F`0,DP`$JM.RL"3$D!1B(U8I2R_P!W$\%JDJ)B$F.;
M@PNE/$05=Y"]B"V7TIZ469#"E@W>A?2@:-@HFP@"02K:M1D7(+W(P>K)4#5%
M$[2;>6$B+E8DPL]@$=3IO4.2(L72`B@3(4JX0A&8""2):T*47NA>@!`)39"*
M8J[9KB9BP`8+32"&;<HOVMWE]'KQ#RAOACS3T<!Z#]TQ$"F,R#-R#84[`S*'
M!=(T4IR`X?0:@)+6%E.A^[5$^05EPZY))AH-MN.UX,SK&Z1%2TGJ5EE@T"08
M520AG\HS,03.IUJ;`NQELLDS#.*.-+$F+X<->Y%!&@`&5;!1J:@1CW"7.C:B
M?!"XP&3(".0C6EF')`6I0ER21HXHU<@E`<J#)#FTM(=62\XHT5DUBA@2=4`N
MD,D(7!+2BI/*JDBZW9B?1;!Z-`AZ20ZK:GX!9T1I\E(!"5DK152W77YI[-8:
MGR@!D3^[F1LT8`!#"DFS&3AJ$`2"51,K9;-V`68*/#:LP+P")TM!;5/]Q18!
M%.22RPL6S0+P9U$J2+Q:QI%-D1("&`$TWR(6J5@=JS84%V*BRP0C5D,D#$(<
M'(%"#*MJCH0Q8(-DY#=8BG;/<K,@@C"K02Z*@V*\OL`#>@DB+U>^#:P5%F%2
M4"UZS:BEYN7OU2@`ASN12._DI)2P#@W8;,TJI;K4SQ;^B,J6"ZQ3DS>9L%T!
M+XE6*YIPSWKH^@$(I/A'(&XEQ)*E_?DA!S:(!I-@KU&]%]T.3:9THU42S`!D
M@#)8B&`V*B4,,$!!D49%&Y)9I=$B+O!DS/!L6*OYC%A1IJ<;L`!@I,94G=65
M\WIZY4+$Q"9>#%T4!``0(@-(N)+N6:3>2P$,>-UYI4MF`RW+3`@AN30J6`4"
MY$$YD%"^K0AH`9&+(),R)EJVHBV)!81S:=Z?"A>NK=#JLJM7?J(73AK\:Y8J
MZ2^%NR^%Y0%@%==`X;VZG3\'ABD(DB;)4XH2FZJ2R5S@ZE$76!&0TM3ZLC<T
M"8.N\*RZE`ZAA$1[GYJ!+BL+W:"^":60Q877L>RC:*MEAZ.Z3$$\UC>D4`U9
M6&P2L-'%J2A)`6*!-UI&D"LS`FH`#-W.$_&:7%*$=3G?O0>!%LTM!;+?D5"B
M'&!L-NT%3(5712.L^U.DA"(H\C^U71![<.F_DWRD[8B4U<Z#['ZIF5=S_+91
MM^F53NAXJ8TQ%>`%'-!&%4V[N`\`]:!EHNV/!LV+10%,L`#L?Y?Q7^[UYO[G
M&$]*]S1=16QQ3=Q3W@[1:KO<1,4N'5XOVJ_L,77?O7#>VDXPC\__V@`(`0,#
M`3\0_!0S4T&V'X":D$>B@>,TDQW1^\4W/8E$;UI;VO[8J_R]C^JQ!&P_-.0!
MPJ_E/G+"#\7J+-^F!V:D_*2GPI9$%I+'P=B7<IM%?$GE%W=!VJ5M-1'<H/FB
MH1L']1X6KSS4>`)^:RI>?V+6,WLVJU%KV:59?!OHI&1;@?4*'NXB)\D_-2I<
MG,M]GDJ8IC9%NTGP5A$EUV"P^'&U!P=4FT]X3L)TFCN*D]%:-<!+KBI<`G<;
M`^1T5H\5=R1OD^NM"$/NWB>,#N+S0&"!H$?C'XP)$T;E!R<Z(]2N.@/-2W29
M"G.H\SHBL:3!HIN.+Z1=BS1IQ"S4^E\=.1)IRL!RT#C4$2O,NJSBN-*,&3(.
MK?ZBGPLZ;%*K"$Y6L\4ZW(`=B_S4#"RJB6>M3EF@IB[K-,S9EM9ML5"2(`X)
MB"C1L`,DK3D`ZVJW-@Y*DBXY:5?^6*!HD*)$Z5!B5.27R[]!0.#MZ3<Z%^DC
M<*F%V$SQZ,<GF9E(3A)G?IZQ+A8="Q\%(7"RPI9YVJ+1:!RIBVVMZB$?U+3I
MC'D8XBD12KF\)CYBE58$JW?_`$J?4)X;M%![DE=]_FD=9'FD`?AIC&5TPF,^
M.:.("`&)%E>\VI0KZ"(HWB+"WLDQ3\`$(W$<C3E$#/L6>Q$1MUHCKL!K<1VB
M/2.UGV"I\KZ,85*!E8J/0HPRW>RC<$`?%+:D9<VTEJPGU9$)B-1OO5U+NHVH
ML5(0"C.<+;>D!,3)&C<B="I:*Y-SBZK`Y2036^0EI=*1!<(.E`$@_:EP69$$
M-YT'Q3@Y1`D`!RBH/`K+&KZ<+'M"HRFWEOV*4*S#-C%WR3F*2L,I.C>'ICI?
MT'4.AJO%8_25P&/NGE]"R!=$XBG[LG9,'66E0+)MB68(V+-.D3=N$V=J-8C6
MW4N>`^:0)(#-*ILDL8X.KO2TP#+&5_HTW*$[X$V&8.LQVI``0O1@\M15$BD#
M`:]5BDL$W#[8?BFD4L+U?1\<SH(OYGXJ0"+#2P7S2"0XJ+%AFF_7](7H#`,B
M4@Y!BMPB3@%0>51H@@DRZ`9>>*+"2"(LNSWFD``8:P3H&Z3M4,!W(P[%C2\E
M"BD&#L;O4+[%1,(+.LL)M8O_`.T$P@:"!]XI0IAWSRXTEUI9$E>!"7%[H$T9
M=BE<KFW3'6H0:P+N9OC:KF$:HF32=_0C!*_ARK8,M3X/PT3P976EI@6>4>1G
MT,`>$?LV3(EQI@<H34]BWH,U@?[#K;.21WJ!6,3QF.2HN%S&YWI:81T^?NL,
M7I-YSYUH`!@100$)CB<QM4FTI<A`^+5/!(A>V*$B<3M.:T6PB>*3D3*3LQB3
M6EI#".U!%(!T`/HI2#=R'3=[+B@SM1O=^3EL%B*M\OCH?9+KZ)-)%()`(Z-2
M.A<N)<1?LLZT3`[8=%SJ#S2L?KS^/FAY16HR?GRXK''O/U2Y)TA=\%,`<["_
M8O2I'XT@=)L'!>@2^JQG8.A_*5N[`<Q&M1Y]8/0X$E#U=R\1#T+WW%12.['X
M&O!5N#U!7P?"D!CD8^U-4/=I1:5KUO[IC"AX+]BK`D\(\T.7@$_**\4EY^I#
MQ88YAHD%7/\`&X]IH::ZOZ;>*#&>`05'^/$>BKWV+2*YOZ&>:\K7=YXQ5HK+
7GQYI<.HOBN+YR?\`NK'26MB.VGY__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
